Important safety considerations include risk of pancreatitis (treatment should be discontinued if suspected), gallbladder disease, and potential worsening of diabetic retinopathy in patients with pre-existing retinopathy who experience rapid improvement in glucose control (particularly with semaglutide)
As more data becomes available, treatment plans will continue to improve
Why it matters: The D2C market for weight loss drugs is becoming harder for companies like Hims to operate in
Non-GLP-1 Medications There are additional weight loss medications available for patients that are often more affordable if you do not have insurance coverage for obesity medications
Structurally similar to insulin, IGF-1 binds to specific receptors on cells, activating pathways that promote cell growth, protein synthesis, and repair
No clinical evidence supports their effectiveness for weight loss